We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.23 | 0.77% | 30.25 | 30.15 | 30.26 | 30.28 | 30.07 | 30.10 | 2,908,982 | 22:20:00 |
By Stephen Nakrosis
Genentech on Friday said the U.S. Food and Drug Administration granted accelerated approval to Tecentriq plus chemotherapy for certain adult breast cancer patients.
The approval was based on data from the Phase III IMpassion130 study, which demonstrated that Tecentriq plus certain chemotherapy drugs significantly reduced the risk of the disease worsening or death, the company said. Safety appeared consistent with the known safety profiles of the individual medicines, and no new safety signals were identified with the combination, the company said.
Genentech said this Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer.
The FDA's Accelerated Approval Program can give faster approval of treatments for serious conditions where there is an unmet medical need.
Genentech is a member of the Roche Group.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 08, 2019 12:55 ET (17:55 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions